How this company measures up on the fundamentals that matter
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $25 against a fair value of $34, a 26% discount. Passes all ethical screens. Ranks better than 95% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | DAMICO JENNIFER B. | Officer | 21,719 | — | |
| 2026-02-25 | SAHNI PAYAL | Officer | 56,888 | $1,923,952 | |
| 2026-02-25 | MCDERMOTT MICHAEL | Officer | 37,925 | $1,282,624 | |
| 2026-02-25 | DAMICO JENNIFER B. | Officer | 17,558 | $593,812 | |
| 2026-02-25 | BOURLA ALBERT | Chief Executive Officer | 491,626 | $16,626,791 | |
| 2026-02-25 | FONSECA LIDIA PH.D. | Officer | 56,888 | $1,923,952 | |
| 2026-02-25 | LANKLER DOUGLAS M | Officer | 122,907 | $4,156,715 | |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Officer | 13,383 | — | |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | 2,500 | $64,825 | |
| 2025-03-04 | DAMICO JENNIFER B. | Officer | 5,583 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15